FDA Restricts Big Pharma Influence on Advisory Panels

---

Full Story

The FDA has announced plans to limit pharmaceutical industry representatives on its advisory committees to reduce corporate influence over decisions. The move aims to ensure impartiality in drug approvals and regulations. It addresses long-standing concerns about conflicts of interest in the agency.

The FDA oversees drug safety and efficacy for the U.S. market. Advisory committees provide expert recommendations on approvals.

MEDIA REPORTING

See how news sources on all sides are covering this story.

Left 34% | Right 28% | Center 31% | Unrated 7%

The Context

Industry representatives often bring technical expertise to these panels. Critics argue their presence risks biased decision-making.

The new policy will likely reduce the number of Big Pharma members. It responds to calls for greater transparency in regulation.

Some support the change, citing improved public trust in the FDA. Others warn it could limit access to industry-specific knowledge.

The FDA has not detailed how it will select future committee members. The policy shift may affect drug approval timelines.

Conflicts of interest have been a recurring issue in FDA history. Past reforms also sought to balance expertise and independence.

Supporters believe the change prioritizes patient safety over profits. Critics fear it may slow innovation in pharmaceuticals.